Dr. Ting Xu returned to China in 2008 and founded Suzhou Alphamab to work on R&D of biologics. He also co-founded several biotech companies from 2011 to 2015. In 2015, Dr. Xu led the spin-out of Alphamab Oncology and then Initial Public Listing (IPO) on the Main Board of the Hong Kong Stock Exchange (stock code: 9966.HK) in 2019. Prior to Alphamab, Dr. Xu held R&D positions in Archemix, Serono and Biogen, where he had been involved in the development of recombinant therapeutics with several launched products.
Dr. Xu has more than 20 years of innovative R&D experience in the biopharmaceutical industry. Dr. Xu had made significant contributions to the evolving of biosimilar industry in China. Through collaboration, he led the development of more than 30 biosimilar drugs, including Bevacizumab (QILU), Recombinant Factor VIII (CTTQ), hCG (Livzon), TSH (SmartNuclide), and Pertuzumab (CTTQ). Dr. Xu invented Envafolimab, the first subcutaneous (subQ) injectable PD-L1 antibody launched in 2021, and more than 10 clinical-stage biologics, potentially FIC or BIC. He also led the establishment of cutting-edge platforms, such as single-domain antibody (sdAb), bispecific antibody, glycan conjugation for antibody-drug conjugate (ADC), dual payload ADC and high-concentration formulation. Dr. Xu’s focus is to develop the multifunctional antibodies and protein drugs with better precision, lower toxicity, and superior efficacy.
Dr. Xu holds a B.S. in Biochemistry from Nanjing University and a Ph.D. from the Chinese Academy of Science. Currently, Dr. Xu holds adjunct professorship in the Shanghai Institute of Materia Medica, the Chinese Academy of Sciences, Nanjing University and Southeast University. He has led 5 national-level projects such as the "Major New Drug Development" special project.
Dr. Xu has received numerous awards including “Major National Talent Programs”, “Suzhou Science and Technology Innovation and Entrepreneurship Mayor Award", "Suzhou Outstanding Talent Award", "Top Ten Scientific and Technological Innovation and Entrepreneurship Figures in Jiangsu" and so on.
Ms. Yang Liu has nearly 30 years of experience in the biotech industry. Prior to Alphamab Oncology, she served as Vice President of Corporate Operations at Dingfu Biotarget, a biotech company focused on Immuno-Oncology. Ms. Liu also has extensive experience in R&D of antibody drug conjugation.
Since joining the company, Ms. Liu has been responsible for corporate operations including human resources, supply chain, engineering, internal control and audit, and public relationship. Ms. Liu played a critical role in building current team from scratch to cover discovery, CMC and clinical development of innovative biologics. She spearheaded a highly efficient finance, sourcing and purchasing, and auditing and compliance system. She strives to promote a corporate culture for an integral, supportive and dedicated environment; particularly diversity women leadership across the company at different management levels.
Mr. Cho Man is a senior economist. From June 2013 to June 2023, Mr. Cho served as an executive director and the president of Shanghai Pharmaceuticals Holding Co., Ltd. and held directorships in certain of its subsidiaries. From September 2020 to September 2024, he served as the chairman of Shanghai Biomedical Industrial Equity Investment Fund Partnership.
Mr. Cho previously held management positions such as chairman and general manager of Wing Fat Printing Co., Ltd., China Resources Pharmaceutical Group Limited, Sanjiu Enterprise Group, etc.
Mr. Cho obtained a bachelor’s degree in pharmacy from Sichuan University (former West China University of Medical Science) and a master’s degree in management from the School of Management of Fudan University.
Dr. GUO Zijian, has been serving as a professor of School of Chemistry and Chemical Engineering of Nanjing University since May 1999. From October 1996 to April 1999, he was a research associate at the University of Edinburgh in the United Kingdom. Dr. Guo was granted the Outstanding Achievement Award by Asian Society of Biological Inorganic Chemistry, Luigi Sacconi Medal from the Italian Chemical Society, the First Prize of China’s State Natural Science Award.
Dr. Guo received his doctor degree from the University of Padova in Italy and worked as a postdoctoral research fellow at Birkbeck College of the University of London in the United Kingdom.
Mr. Wei Kevin Cheng is a managing partner of a corporate finance advisory firm, with over 29 years of experiences in audit, financial management and board corporate governance at publicly listed companies. Mr. Wei previously served as CFO for Solarfun Power Holdings and IFM Investment Limited, both were publicly listed companies in U.S.
Mr. Wei currently serves as the chairman of the board, an independent non-executive director and the chairman of audit committee of Tibet Water Resources Ltd. (stock code: 1115); an independent non-executive director and the chairman of audit and compliance committee of Nexteer Automotive Group Limited (stock code: 1316), both are listed on the Hong Kong Stock Exchange.
Mr. Wei graduated with a bachelor’s degree with a double major in accounting and business administration from Central Washington University in the U.S. He is a member of the American Institute of Certified Public Accountants.
Mr. Dong Wu is a venture partner at 6 Dimensions Capital. Mr. Wu worked for Johnson & Johnson for over 10 years and served different positions including the head of Asia Pacific Innovation Center, a vice president of global engineering and emerging market research and development, the Emerging Market Innovation Centre Leader, a vice president of Research Development & Engineering, Asia Pacific and a senior director of emerging market research and development. Mr. Wu is currently the founder and an executive director of Shanghai Jiuben Technology Co., Ltd.
Mr. Wu received his bachelor’s degree in applied chemistry from Fudan University and an executive Master of Business Administration from China-Europe International Business School.
